TY - JOUR
T1 - Drug delivery in intervertebral disc degeneration and osteoarthritis
T2 - Selecting the optimal platform for the delivery of disease-modifying agents
AU - Colella, Fabio
AU - Garcia, João Pedro
AU - Sorbona, Marco
AU - Lolli, Andrea
AU - Antunes, Bernardo
AU - D'Atri, Domenico
AU - Barré, Florian P.Y.
AU - Oieni, Jacopo
AU - Vainieri, Maria Letizia
AU - Zerrillo, Luana
AU - Capar, Serdar
AU - Häckel, Sonja
AU - Cai, Yunpeng
AU - Creemers, Laura B.
N1 - Acknowledgement
We would like to acknowledge Prof. Gerjo Van Osch and prof Molly Stevens for their careful and critical revision of the manuscript. We wish to thank all principal investigators of the TargetCaRe consortium for their enormous support during the years: Prof G. van Osch. Prof. Mauro Alini, Prof. Bruce Caterson, Dr. Alan Chan, Prof. Cosimo De Bari, Prof. Ron Heeren, Prof. Kennet Howard, Prof. Marcelle Machluf, Prof. Molly M. Stevens and Prof. Avner Yayon.
This work was supported by European Union's Horizon 2020 Research And Innovation Programme under Marie Sklodowska Curie Grant agreement no. 642414.
PY - 2020/12/10
Y1 - 2020/12/10
N2 - Osteoarthritis (OA) and intervertebral disc degeneration (IVDD) as major cause of chronic low back pain represent the most common degenerative joint pathologies and are leading causes of pain and disability in adults. Articular cartilage (AC) and intervertebral discs are cartilaginous tissues with a similar biochemical composition and pathophysiological aspects of degeneration. Although treatments directed at reversing these conditions are yet to be developed, many promising disease-modifying drug candidates are currently under investigation. Given the localized nature of these chronic diseases, drug delivery systems have the potential to enhance therapeutic outcomes by providing controlled and targeted release of bioactives, minimizing the number of injections needed and increasing drug concentration in the affected areas. This review provides a comprehensive overview of the currently most promising disease-modifying drugs as well as potential drug delivery systems for OA and IVDD therapy.
AB - Osteoarthritis (OA) and intervertebral disc degeneration (IVDD) as major cause of chronic low back pain represent the most common degenerative joint pathologies and are leading causes of pain and disability in adults. Articular cartilage (AC) and intervertebral discs are cartilaginous tissues with a similar biochemical composition and pathophysiological aspects of degeneration. Although treatments directed at reversing these conditions are yet to be developed, many promising disease-modifying drug candidates are currently under investigation. Given the localized nature of these chronic diseases, drug delivery systems have the potential to enhance therapeutic outcomes by providing controlled and targeted release of bioactives, minimizing the number of injections needed and increasing drug concentration in the affected areas. This review provides a comprehensive overview of the currently most promising disease-modifying drugs as well as potential drug delivery systems for OA and IVDD therapy.
UR - http://www.scopus.com/inward/record.url?scp=85090558186&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2020.08.041
DO - 10.1016/j.jconrel.2020.08.041
M3 - Review article
C2 - 32860929
AN - SCOPUS:85090558186
VL - 328
SP - 985
EP - 999
JO - Journal of Controlled Release
JF - Journal of Controlled Release
SN - 0168-3659
ER -